FDA approves Aurobindo's olopatadine hydrochloride solution

DAYTON, N.J. — Aurbindo on Monday announced that it has received approval from the Food and Drug Administration for its olopatadine hydrochloride ophthalmic solution USP, 0.1%, a bioequivalent version of Alcon's Patanol.

Olopatadine hydrochloride ophthalmic solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

The solution had sales of $234.5 million for the twelve months ended October 2015, according to IMS.